Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.51 |
| ▸ | CA1 | P00915 | 6/20 | 0.51 |
| ▸ | CA2 | P00918 | 6/20 | 0.51 |
| ▸ | CA7 | P43166 | 6/20 | 0.51 |
| ▸ | CA9 | Q16790 | 6/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.48 |
| ▸ | GABRP | O00591 | 6/20 | 0.48 |
| ▸ | GABRD | O14764 | 6/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30234144 | 1.00 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL9520152 | 0.98 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL27267432 | 0.86 | CA12 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL127699 | 0.84 | CYP1A2 (0.53) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL15842178 | 0.84 | ESR1 (0.54) | CYP1A2ESR1NR1H2MAPTALDH1A1 | |
| SCHEMBL2360263 | 0.83 | TSHR (0.50) | CYP1A2ESR1NR1H2MAPTALDH1A1 | |
| SCHEMBL29466587 | 0.83 | JMJD6 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30440953 | 0.83 | CYP1A2 (0.51) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL159881 | 0.83 | CYP1A2 (0.51) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL930636 | 0.83 | JMJD6 (0.57) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459923-B2 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-3787621-B1 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240228464-A9 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228464-A9 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228464-A9 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240132476-A1 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2024-04-25 | — | — | US | disclosed |
| CN-112312905-B | Tetrazole-containing inhibitors of apoptosis signal-regulating kinase 1 and methods of use thereof | 英安塔制药有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11834436-B2 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834436-B2 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834436-B2 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-1227084-B1 | DRUG DISCHARGE PUMP INHIBITORS | TRINE PHARMACEUTICALS INC (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050009843-A1 | Medicine for inhibiting drug elimination pump | TRINE PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
| EP-1389463-A1 | MEDICINE FOR INHIBITING DRUG ELIMINATION PUMP | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| US-20030092720-A1 | Drug efflux pump inhibitor | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2003-05-15 | — | — | US | disclosed |
| CN-1414951-A | Drug discharge pump inhibitor | FUNDAMENTAL THERAPEUTICAL INC (US) | 2003-04-30 | — | — | CN | disclosed |
| EP-1227084-A1 | DRUG DISCHARGE PUMP INHIBITORS | Microcide Pharmaceuticals, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| CN-1028024-C | Tetrazole excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 1995-03-29 | — | — | CN | disclosed |
| CN-1048385-A | TETRAZOLE EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1991-01-09 | — | — | CN | disclosed |
| EP-0405834-A2 | Tetrazole excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1991-01-02 | — | — | EP | disclosed |
| EP-0330353-A1 | Tetrazole excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459923-B2 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | AIFM1, BAD, IRAK1 | CA12 4572/4885CA1 2567/4885CA2 3461/4885 |
| US-20030092720-A1 | Drug efflux pump inhibitor | ABCB11, ABCB1, ABCC1 | CA12 4805/4885CA1 4826/4885CA2 2865/4885 |
| US-11834436-B2 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | AIFM1, BAD, IRAK1 | CA12 4572/4885CA1 2567/4885CA2 3461/4885 |
| US-20240228464-A9 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | AIFM1, BAD, IRAK1 | CA12 4572/4885CA1 2567/4885CA2 3461/4885 |
| US-20240132476-A1 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | AIFM1, BAD, IRAK1 | CA12 4572/4885CA1 2567/4885CA2 3461/4885 |
| US-20050009843-A1 | Medicine for inhibiting drug elimination pump | ABCB11, ATP6AP1, HRH2 | CA12 4468/4885CA1 4434/4885CA2 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.